Five years ago, Biomet was in turmoil, as the board announced the company was for sale and the company's long-time CEO stepped down. The eventual buyers: a group of leading private equity firms. Biomet still faced a number of internal challenges, including fixing a spine and trauma business that was performing poorly. Critical to Biomet's turnaround was re-establishing the culture of stability that had long characterized the company. At the same time, it now has a new, more aggressive focus on capturing market share commensurate with its role as a top orthopedics company.
by David Cassak
It's hard to imagine a company, particularly a public company, that's ever gone through a more difficult time than
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.